Daddio v. A.I. DuPont Hospital for Children of the Nemours Foundation

650 F. Supp. 2d 387, 80 Fed. R. Serv. 482, 2009 U.S. Dist. LEXIS 74834
CourtDistrict Court, E.D. Pennsylvania
DecidedAugust 21, 2009
DocketCivil Action 05-441
StatusPublished
Cited by10 cases

This text of 650 F. Supp. 2d 387 (Daddio v. A.I. DuPont Hospital for Children of the Nemours Foundation) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Daddio v. A.I. DuPont Hospital for Children of the Nemours Foundation, 650 F. Supp. 2d 387, 80 Fed. R. Serv. 482, 2009 U.S. Dist. LEXIS 74834 (E.D. Pa. 2009).

Opinion

MEMORANDUM

McLAUGHLIN, District Judge.

Robert and Tracie Daddio bring this medical negligence action under Delaware law seeking damages for the death of their son, Michael Daddio. Michael died approximately twenty months after undergoing pediatric cardiac surgery to correct his congenital heart defects at the A.I. duPont Hospital for Children (the “duPont Hospital”) in Wilmington, Delaware. The defendants are the Nemours Foundation, which owns and operates the Nemours Cardiac Center at the duPont Hospital, and Dr. William I. Norwood, the pediatric heart surgeon who operated on Michael. The plaintiffs state two claims against the defendants. First, they claim that Michael received negligent care and treatment from the defendants, which resulted in his death. Second, they claim that they did *391 not give their informed consent to a procedure Michael underwent. 1

This case came to this Court in September 2008, following an appeal in a related case, Svindland, et al. v. The Nemours Foundation, et al., Civ. A. No. 05-417. After that appeal, both the Svindland case and this case were transferred to the undersigned. The Court held a status conference with the parties in September 2008, at which time the parties informed the Court that the case was all but ready for trial, and that a limited number of issues remained to be decided, including the admissibility of testimony from the plaintiffs’ expert witness, Dr. Robert L. Hannan. Following the September 2008 conference, the defendants filed a motion to preclude certain testimony by Dr. Han-nan under Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), and Rule 702 of the Federal Rules of Evidence.

The Court held a hearing on this motion and other evidentiary motions on March 11, 2009. At that hearing, at which the plaintiffs did not offer testimony from Dr. Hannan, plaintiffs’ counsel explained that they were uncertain as to Dr. Hannan’s theory of causation. Rather than decide the motion, the Court allowed the plaintiffs the opportunity to attempt to clarify their position at a later date.

Following the March 11, 2009, hearing, the plaintiffs filed various additional submissions with the Court, including an affidavit from Dr. Hannan, attempting to clarify their theory of the case. Throughout the period following the hearing, and up until the pretrial conference on June 24, 2009, at which new counsel for the plaintiffs appeared, the Court understood the plaintiffs’ theory of causation to be something other than what they now argue it to be.

At the final pretrial conference, the Court continued to express concern about the reliability of Dr. Hannan’s testimony. Accordingly, the Court allowed the plaintiffs yet another opportunity to present testimony from Dr. Hannan at a special hearing on July 7, 2009. Following a hearing with Dr. Hannan on that date, the parties agreed to postpone trial so that the plaintiffs might have a final opportunity to clarify their position on the scope and content of Dr. Hannan’s expert testimony, and so that the defendants might have the opportunity to respond.

The defendants continue to argue that Dr. Hannan’s testimony is not reliable under Daubert and Rule 702-both the theories that they originally moved to preclude and the theories since argued by new counsel for the plaintiffs. They have also since filed a motion for summary judgment on the basis that the plaintiffs have not provided any other evidence of causation to support their medical negligence or informed consent claims.

Upon consideration of the various filings submitted to the Court since September 2008, and having heard from Dr. Hannan himself, the Court concludes that Dr. Han-nan’s proposed testimony, as it has been presented to the Court, is not supported by reliable scientific data and methods. The Court will grant the defendants’ Daubert motion and will preclude Dr. Hannan from presenting testimony that any of the defendants’ alleged acts of negligence caused Michael Daddio’s injuries. The Court will also grant the defendants’ motion for summary judgment, and will enter judgment for the defendants on the plain *392 tiffs’ medical negligence and informed consent claims.

1. Factual Background and Procedural History

Michael Daddio was born on June 5, 2001, with multiple congenital heart defects, including a condition known as Hypoplastic Left Heart Syndrome (“HLHS”). To survive, Michael needed three surgical procedures to alter the flow of blood through his heart. The first of these surgeries is commonly referred to as the “Norwood procedure.” The second is commonly referred to as the “hemi-Fontan” procedure. The third is known as the “Fontan” or “Fontan completion” procedure.

On June 7, 2001, Dr. Norwood performed the first of three scheduled surgeries to correct Michael’s heart defects. A second surgery was performed on November 9, 2001. At some point after the second surgery, Michael developed persistent pleural effusions, which are liquid buildups surrounding the lungs. Michael died approximately twenty months later, on July 23, 2003.

Prior to both of Michael’s surgeries, Dr. Norwood utilized a technique known as “deep hypothermic circulatory arrest” (“DHCA”), in which the body is cooled to a certain temperature, blood is removed and stored, and the surgeon operates in a bloodless field on a heart that does not beat. Cooling serves the purpose of reducing the amount of oxygen required by the body’s organs in the absence of blood flow. In their operative complaint, the plaintiffs asserted that Dr. Norwood’s cooling technique was negligent, as was the manner in which he used circulatory arrest. See Am. Compl. ¶ 32. They did not identify any other ways in which Dr. Nor-wood’s conduct was negligent.

This case was originally assigned to the Honorable Berle M. Schiller of the United States District Court for the Eastern District of Pennsylvania. 2 Judge Schiller was also the trial judge assigned to another case brought against Dr. Norwood and the Nemours Foundation, Svindland, et al. v. The Nemours Foundation, et al., Civ. A. No. 05-417.

Upon agreement of the parties, these two cases were consolidated for the purposes of discovery with other cases filed against the defendants. Pursuant to a stipulation filed by the parties, Judge Schiller would decide discovery issues that were common to all cases; other disputes would be decided by whichever judge was sitting as the trial judge. See Svindland Docket No. 20; Daddio Docket No. 21.

A. Dr. Hannan’s Report and Deposition

By letter dated September 28, 2006, Dr. Hannan expressed his criticisms of Dr. Norwood’s treatment of Michael Daddio. See

Free access — add to your briefcase to read the full text and ask questions with AI

Related

WICHTERMAN v. CITY OF PHILADELPHIA
E.D. Pennsylvania, 2020
CHEN v. AMTRAK
E.D. Pennsylvania, 2019
Ellison v. United States
753 F. Supp. 2d 468 (E.D. Pennsylvania, 2010)
Robert Daddio v. The Nemours Foundation
399 F. App'x 711 (Third Circuit, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
650 F. Supp. 2d 387, 80 Fed. R. Serv. 482, 2009 U.S. Dist. LEXIS 74834, Counsel Stack Legal Research, https://law.counselstack.com/opinion/daddio-v-ai-dupont-hospital-for-children-of-the-nemours-foundation-paed-2009.